IMTIB   27019
INSTITUTO DE MEDICINA TRASLACIONAL E INGENIERIA BIOMEDICA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
In patients with Nonalcoholic Fatty Liver Disease significant fibrosis and the active nonalcoholic steatohepatitis is associated with a moderate-high cardiovascular risk at 10 years.
Autor/es:
CASCIATO P; N. SOBENKO; DIAZ J; DE LA VIÑA ; C. BERMUDEZ; GUTIERREZ ACEVEDO ; REYES BUSTAMANTE R; GADANO A; MAURO E.; NARVAEZ A; ORTIZ PATRON J; MASSON W
Lugar:
SEvila
Reunión:
Simposio; SUMMIT NAFLD simposio; 2019
Institución organizadora:
European Association Study Liver Disease
Resumen:
The presence of non-alcoholic steatohepatitis (NASH) and advanced fibrosis are strongly associated with cardiovascular mortality. Currently it is unknown whether the cut-offs established by non-invasive methods (FIB-4, NAFLD score, and Fibroscan®) or the presence of active histological NASH (NAS≥4) and significant fibrosis (F≥2), could predict cardiovascular risk (CVR). AIM: To evaluate the association between the presence of NASH (NAS≥4-F≥2) in liver biopsy with CVR ≥7.5 at 10 years estimated by atherosclerotic cardiovasculardisease (ASCVD). 2- To evaluate the diagnostic capacity of non-invasive methods to estimate an RCV ≥7.5% at 10 years. 3- To evaluate the CVR in patients with NASH lean (BMI 1.3), NAFLD score (> -1.455) and Fibroscan® (≥8 kPa)] was evaluated by analysis of the area under the curve (AUROC), establishing the respective sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV). RESULTS:We included 214 patients (55% female), median age of 58 (49-65) years. The prevalence of obesity, smoking, diabetes, hypertension, dyslipidemia and NASH were: 62%, 23%, 41%, 54%, 71% and 8%, respectively. The prevalence of significant fibrosis, NASH NAS≥4-F≥2 and advanced fibrosis was: 37%, 35% and 18%, respectively. The prevalence of CVR ≥7.5% at 10 years was 54%. The independent factors associated with CVR ≥7.5% at 10 years were the presence of NASH NAS≥4-F≥2 (OR: 2.45, 95% CI 1.27-4.73, p = 0.008), and eGFR MDRD4 (OR: 0.97, 95% CI 0.96-0.98, p